{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:05:27Z","timestamp":1793480727570,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DC12519"],"award-info":[{"award-number":["R01-DC12519"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DC14942"],"award-info":[{"award-number":["R01-DC14942"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-NS89757"],"award-info":[{"award-number":["R01-NS89757"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1-NS112153"],"award-info":[{"award-number":["RF1-NS112153"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NeuroImage"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.neuroimage.2024.120509","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T12:45:27Z","timestamp":1704372327000},"page":"120509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Direct comparison between 18F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsy"],"prefix":"10.1016","volume":"286","author":[{"given":"Ryota","family":"Satoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farwa","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2930-8634","authenticated-orcid":false,"given":"Keith A.","family":"Josephs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Whitwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroimage.2024.120509_bib0001","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0002","unstructured":"Bilgic, B., Costagli, M., Chan, K.-.S., Duyn, J., Langkammer, C., Lee, J., Li, X., Liu, C., Marques, J.P., Milovic, C., Robinson, S., Schweser, F., Shmueli, K., Spincemaille, P., Straub, S., Zijl, P.v., Wang, Y., 2023. Recommended implementation of quantitative susceptibility mapping for clinical research in the brain: a consensus of the ISMRM ElectroMagnetic Tissue Properties Study Group. arXiv:2307.02306."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0003","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/gps.4756","article-title":"A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores","volume":"33","author":"Carson","year":"2018","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mds.26844","article-title":"Subcortical (18)F-AV-1451 binding patterns in progressive supranuclear palsy","volume":"32","author":"Cho","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2967\/jnumed.117.195248","article-title":"Off-target (18)F-AV-1451 binding in the basal ganglia correlates with age-related iron accumulation","volume":"59","author":"Choi","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2023.120068","article-title":"Multimodal comparisons of QSM and PET in neurodegeneration and aging","volume":"273","author":"Cogswell","year":"2023","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2020.117433","article-title":"Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers","volume":"224","author":"Cogswell","year":"2021","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0008","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/WCO.0b013e32833be924","article-title":"Neuropathology of variants of progressive supranuclear palsy","volume":"23","author":"Dickson","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0009","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neuroimage.2017.05.015","article-title":"Toward defining deep brain stimulation targets in MNI space: a subcortical atlas based on multimodal MRI, histology and structural connectivity","volume":"170","author":"Ewert","year":"2018","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0010","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0011","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0012","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/mds.28901","article-title":"Brainstem biomarkers of clinical variant and pathology in progressive supranuclear palsy","volume":"37","author":"Grijalva","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0013","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/mds.27666","article-title":"How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy","volume":"34","author":"Grimm","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0014","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1212\/WNL.44.11.2015","article-title":"Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)","volume":"44","author":"Hauw","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0016","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0017","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00234-017-1870-7","article-title":"Differential diagnosis of parkinsonism by a combined use of diffusion kurtosis imaging and quantitative susceptibility mapping","volume":"59","author":"Ito","year":"2017","journal-title":"Neuroradiology"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0018","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s00415-022-11556-3","article-title":"Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysis","volume":"270","author":"Jin","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0019","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/01.jnen.0000218446.38158.61","article-title":"Atypical progressive supranuclear palsy with corticospinal tract degeneration","volume":"65","author":"Josephs","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.25259\/SNI_584_2021","article-title":"Volumetric analysis of subthalamic nucleus and red nucleus in patients of advanced Parkinson's disease using SWI sequences","volume":"12","author":"Kolpakwar","year":"2021","journal-title":"Surg. Neurol. Int."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2021.725731","article-title":"Quantitative susceptibility mapping of the basal ganglia and thalamus at 9.4 Tesla","volume":"15","author":"Kumar","year":"2021","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0023","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.neuroimage.2012.05.049","article-title":"Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study","volume":"62","author":"Langkammer","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0024","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.2613","article-title":"Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export","volume":"18","author":"Lei","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neuroimage.2014.12.043","article-title":"A method for estimating and removing streaking artifacts in quantitative susceptibility mapping","volume":"108","author":"Li","year":"2015","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0026","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.neuroimage.2011.10.038","article-title":"Magnetic susceptibility anisotropy of human brain in vivo and its molecular underpinnings","volume":"59","author":"Li","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0027","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 Tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0028","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ana.24844","article-title":"Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies","volume":"81","author":"Marquie","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0029","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.nicl.2016.11.015","article-title":"9.4 T MR microscopy of the substantia nigra with pathological validation in controls and disease","volume":"13","author":"Massey","year":"2017","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fninf.2016.00020","article-title":"VoxelStats: a MATLAB package for multi-modal voxel-wise brain image analysis","volume":"10","author":"Mathotaarachchi","year":"2016","journal-title":"Front. Neuroinform."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0031","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2967\/jnumed.120.252254","article-title":"Brain tau imaging: food and drug administration approval of (18)F-flortaucipir injection","volume":"61","author":"Mattay","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0032","first-page":"2053","article-title":"Comparative evaluation of MR-based partial-volume correction schemes for PET","volume":"40","author":"Meltzer","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0033","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0034","first-page":"781","article-title":"18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy","volume":"140","author":"Passamonti","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0035","first-page":"1531","article-title":"Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy","volume":"152","author":"P\u00e9rez","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0036","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1148\/radiol.2453061703","article-title":"MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy","volume":"246","author":"Quattrone","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0037","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fnmol.2018.00276","article-title":"Untangling tau and iron: exploring the interaction between iron and tau in neurodegeneration","volume":"11","author":"Rao","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2023.103394","article-title":"Spatial patterns of elevated magnetic susceptibility in progressive apraxia of speech","volume":"38","author":"Satoh","year":"2023","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0039","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/mds.29613","article-title":"Magnetic susceptibility in progressive supranuclear palsy variants, Parkinson's disease, and corticobasal syndrome","volume":"38","author":"Satoh","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0040","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1364\/OL.28.001194","article-title":"Fast phase unwrapping algorithm for interferometric applications","volume":"28","author":"Schofield","year":"2003","journal-title":"Opt. Lett."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0041","first-page":"792","article-title":"The Mayo Clinic Adult Lifespan Template: better quantification across the lifespan","volume":"13","author":"Schwarz","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2022.119357","article-title":"Face recognition from research brain PET: an unexpected PET problem","volume":"258","author":"Schwarz","year":"2022","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2022.103161","article-title":"Distinct brain iron profiles associated with logopenic progressive aphasia and posterior cortical atrophy","volume":"36","author":"Singh","year":"2022","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0044","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.parkreldis.2017.08.029","article-title":"Quantitative susceptibility mapping differentiates between parkinsonian disorders","volume":"44","author":"Sjostrom","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0045","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1038\/s41598-019-42565-4","article-title":"Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism","volume":"9","author":"Sjostrom","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0046","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/mds.26813","article-title":"Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy","volume":"32","author":"Smith","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0047","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.neuroimage.2014.11.010","article-title":"Validation of quantitative susceptibility mapping with Perls' iron staining for subcortical gray matter","volume":"105","author":"Sun","year":"2015","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0048","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/mds.27365","article-title":"Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease","volume":"33","author":"Taniguchi","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0049","first-page":"59","article-title":"Mediation: R package for causal mediation analysis","author":"Tingley","year":"2014","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.27271","article-title":"The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases","volume":"33","author":"Vermeiren","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0051","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/mrm.25358","article-title":"Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker","volume":"73","author":"Wang","year":"2015","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0052","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/mds.27038","article-title":"Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?","volume":"32","author":"Whitwell","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0053","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mds.26834","article-title":"[(18) F]AV-1451 tau positron emission tomography in progressive supranuclear palsy","volume":"32","author":"Whitwell","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0054","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archneurol.2011.107","article-title":"Clinical correlates of white matter tract degeneration in progressive supranuclear palsy","volume":"68","author":"Whitwell","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.parkreldis.2014.01.023","article-title":"Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes","volume":"20","author":"Whitwell","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.102152","article-title":"Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants","volume":"25","author":"Whitwell","year":"2020","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.neuroimage.2024.120509_bib0057","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/brain\/awm104","article-title":"Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome","volume":"130","author":"Williams","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0058","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1007\/s00259-022-05822-9","article-title":"Monoamine oxidase binding not expected to significantly affect [(18)F]flortaucipir PET interpretation","volume":"49","author":"Wright","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neuroimage.2024.120509_bib0059","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/mrm.23000","article-title":"Whole brain susceptibility mapping using compressed sensing","volume":"67","author":"Wu","year":"2012","journal-title":"Magn. Reson. Med."}],"container-title":["NeuroImage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053811924000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053811924000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:24:23Z","timestamp":1760959463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053811924000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":59,"alternative-id":["S1053811924000041"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroimage.2024.120509","relation":{},"ISSN":["1053-8119"],"issn-type":[{"value":"1053-8119","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct comparison between 18F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsy","name":"articletitle","label":"Article Title"},{"value":"NeuroImage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroimage.2024.120509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"120509"}}